Home
Resources
Publications
Irsogladine Maleate Reduces the Incidence of Fluorouracil-Based Chemotherapy-Induced Oral Mucositis

Irsogladine Maleate Reduces the Incidence of Fluorouracil-Based Chemotherapy-Induced Oral Mucositis

M Nomura, M Kamata, H Kojima, K Hayashi, S Sawada

Ann Oncol. 2013 Apr;24(4):1062-6.

PMID: 23152361

Abstract:

Background:
Oral mucositis is one of the most common side-effects of 5-fluorouracil (5-FU)-based chemotherapy. The objective of this study was to evaluate the effects of irsogladine maleate (IM) on fluorouracil-induced oral mucositis through a double-blind, placebo controlled trial.
Patients and methods:
Patients (N = 66) were randomly assigned to receive either placebo or IM (4 mg/day for 14 consecutive days). The incidence and maximum severity of fluorouracil-induced oral mucositis and safety of the irsogladine dosing regimen were evaluated.
Results:
A cohort of 33 patients received placebo and 33 patients received IM. The incidence of oral mucositis was significantly lower for IM than for placebo (27% versus 73%; P < 0.001 by chi-square test). Specific adverse events considered related to IM were not found.
Conclusion:
IM significantly reduced the incidence and maximum severity of oral mucositis in patients treated with 5-FU-chemotherapy.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP84504698	Irsogladine maleate		84504-69-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: